Company news

Assertio Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors

November 13, 2023

Assertio Reports Third Quarter 2023 Financial Results

November 7, 2023

Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023

November 1, 2023

Assertio Reports Second Quarter 2023 Financial Results, Closes Spectrum Acquisition

August 2, 2023

Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

July 30, 2023

Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals

July 26, 2023

Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

July 23, 2023

Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.

July 19, 2023

Assertio Holdings Joins Russell 3000® Index

June 25, 2023

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

May 8, 2023

Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook

May 8, 2023

Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11: 30 am Eastern Time

May 4, 2023

Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 26, 2023

Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

April 24, 2023

Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits

April 23, 2023

Assertio Reports Fourth Quarter and Full Year 2022 Financial Results

March 7, 2023

Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical

March 5, 2023

Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027

February 22, 2023

Assertio Holdings, Inc. Announces Preliminary Fourth Quarter and Full Year 2022 Results

February 20, 2023

Assertio to Participate in the 2023 Winter Wonderland Best Ideas Conference

February 15, 2023

Assertio to Participate in the 2023 SVB Securities Global Biopharma Conference

February 7, 2023

Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

January 16, 2023

Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent

January 8, 2023

Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco

December 12, 2022

Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million

December 4, 2022

Assertio Reports Third Quarter 2022 Financial Results

November 7, 2022

Assertio Holdings, Inc. to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

October 26, 2022

Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.

October 26, 2022

Assertio to Participate in October 2022 Investor Conferences

October 11, 2022

Assertio to Participate in the 2022 Lake Street BIG6 Conference

September 6, 2022

Assertio Announces Closing of $70 Million Convertible Senior Notes Offering

August 24, 2022

Assertio Prices $60 Million Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024

August 21, 2022

Assertio Announces Proposed Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024

August 21, 2022

Assertio Reports Second Quarter 2022 Financial Results

August 7, 2022

Assertio Holdings, Inc. To Report Second Quarter 2022 Financial Results on Monday, August 8, 2022

July 24, 2022

Assertio Reports First Quarter 2022 Financial Results

May 8, 2022

Assertio Holdings, Inc. to Report First Quarter 2022 Financial Results After the Close of Markets on Monday, May 9, 2022

April 21, 2022

Assertio Holdings, Inc. Partners with BlinkRx to Support Healthcare Providers and Patients Utilizing Otrexup® (methotrexate) with a Unique Patient Access Solution

March 30, 2022

Assertio Reports Fourth Quarter and Full Year 2021 Financial Results

March 8, 2022

Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results Before the Opening of Markets on Wednesday, March 9, 2022

March 1, 2022

Assertio Holdings, Inc. Announces the Acquisition of Otrexup® (methotrexate) a Drug Device Combination from Antares Pharma, Inc.

December 14, 2021

Assertio Holdings, Inc. Announces Preliminary Court Approval of Shareholder Derivative Settlement

November 11, 2021

Assertio Reports Third Quarter 2021 Financial Results

November 3, 2021

Assertio Holdings, Inc. to Report Third Quarter 2021 Financial Results After the Close of Markets on Thursday, November 4, 2021

October 25, 2021

Assertio Reports Second Quarter 2021 Financial Results

August 4, 2021

Assertio Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 3, 2021

Assertio Holdings, Inc. Announces Adjournment of Annual Meeting of Shareholders

May 16, 2021

Assertio Holdings, Inc. Announces 1-for-4 Reverse Stock Split

May 16, 2021

Assertio Reports First Quarter 2021 Financial Results

May 5, 2021

Assertio Holdings, Inc. Partners with Cove, a Leading Migraine Telemedicine Platform, To Launch Direct to Patient Digital Campaign to Increase Accessibility of CAMBIA® (diclofenac potassium) and SPRIX® (ketorolac tromethamine)

May 4, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks